PT3146065T - Métodos e composições para reduzir a infecção por clostridium difficile - Google Patents
Métodos e composições para reduzir a infecção por clostridium difficileInfo
- Publication number
- PT3146065T PT3146065T PT157960006T PT15796000T PT3146065T PT 3146065 T PT3146065 T PT 3146065T PT 157960006 T PT157960006 T PT 157960006T PT 15796000 T PT15796000 T PT 15796000T PT 3146065 T PT3146065 T PT 3146065T
- Authority
- PT
- Portugal
- Prior art keywords
- compositions
- methods
- clostridium difficile
- difficile infection
- reducing
- Prior art date
Links
- 208000037384 Clostridium Infections Diseases 0.000 title 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 title 1
- 206010054236 Clostridium difficile infection Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01159—7-Alpha-hydroxysteroid dehydrogenase (1.1.1.159)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462000308P | 2014-05-19 | 2014-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3146065T true PT3146065T (pt) | 2025-01-14 |
Family
ID=54554650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT157960006T PT3146065T (pt) | 2014-05-19 | 2015-05-19 | Métodos e composições para reduzir a infecção por clostridium difficile |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20170087196A1 (pt) |
| EP (3) | EP4527400A3 (pt) |
| AU (3) | AU2015264266A1 (pt) |
| CA (1) | CA2949232A1 (pt) |
| DK (1) | DK3146065T3 (pt) |
| ES (1) | ES3000403T3 (pt) |
| FI (1) | FI3146065T3 (pt) |
| PT (1) | PT3146065T (pt) |
| WO (1) | WO2015179437A1 (pt) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2899925A1 (en) | 2013-02-04 | 2014-08-07 | Seres Therapeutics, Inc. | Compositions and methods for inhibition of pathogenic bacterial growth |
| WO2016210384A2 (en) | 2015-06-25 | 2016-12-29 | Synlogic, Inc. | Bacteria engineered to treat metabolic diseases |
| WO2017100420A1 (en) * | 2015-12-08 | 2017-06-15 | Mayo Foundation For Medical Education And Research | Biomarkers for predicting clostridium difficile infection treatment outcome |
| WO2017123592A1 (en) * | 2016-01-11 | 2017-07-20 | Synlogic, Inc. | Bacteria engineered to treat disorders associated with bile salts |
| US11260083B2 (en) | 2016-03-15 | 2022-03-01 | The Regents Of The University Of Michigan | Compositions and methods for treating and preventing graft versus host disease |
| JP7168558B2 (ja) | 2016-06-14 | 2022-11-09 | ヴェダンタ バイオサイエンシーズ インコーポレーテッド | Clostridium difficile感染症の処置 |
| US9999641B2 (en) | 2016-06-14 | 2018-06-19 | Vedanta Biosciences, Inc. | Treatment of clostridium difficile infection |
| WO2018195180A1 (en) * | 2017-04-18 | 2018-10-25 | University Of Florida Research Foundation, Incorporated | Materials and methods for the treatment of enteric bacterial infections and associated pathologies including colorectal cancer |
| WO2018195467A1 (en) | 2017-04-21 | 2018-10-25 | Memorial Sloan-Kettering Cancer Center | Lantibiotics, lantibiotic-producing bacteria, compositions and methods of production and use thereof |
| WO2018229519A1 (en) * | 2017-06-12 | 2018-12-20 | Debreceni Egyetem | Methods for diagnosing breast cancer |
| KR102323783B1 (ko) * | 2017-09-22 | 2021-11-09 | 주식회사 고바이오랩 | 클로스트리디움 디피실레(Clostridium difficile) 성장 억제효과를 갖는 클로스트리디움 신덴스 균주 |
| JP2021501185A (ja) * | 2017-10-30 | 2021-01-14 | セレス セラピューティクス インコーポレイテッド | 抗生物質耐性を処置するための組成物及び方法 |
| WO2019118510A1 (en) * | 2017-12-11 | 2019-06-20 | The Brigham And Women's Hospital, Inc. | Defined therapeutic microbiota and methods of use thereof |
| US20200368293A1 (en) * | 2018-01-18 | 2020-11-26 | Vedanta Biosciences, Inc. | Compositions and methods for the treatment of cancer |
| WO2020037271A1 (en) | 2018-08-17 | 2020-02-20 | Vedanta Biosciences, Inc. | Methods of decreasing dysbiosis and restoring a microbiome |
| EP3914091B1 (en) | 2019-01-23 | 2025-09-17 | Mars, Incorporated | Methods and compositions for treating intestinal disorder |
| WO2020171255A1 (ko) * | 2019-02-21 | 2020-08-27 | 서울대학교산학협력단 | 클로스트리디움 디피실레(clostridium difficile) 성장 억제효과를 갖는 클로스트리디움 신덴스 균주 |
| EP3952864A4 (en) | 2019-03-08 | 2023-05-10 | The Regents of the University of California | COMPOSITIONS AND METHODS FOR MODULATION OF LIPID AND STEROID METABOLISM |
| AU2020251289A1 (en) * | 2019-04-02 | 2021-10-14 | National University Of Singapore | Engineered dysbiosis-sensing probiotic for clostridiumdifficile infections and recurring infections management |
| WO2021163212A1 (en) | 2020-02-10 | 2021-08-19 | Native Microbials, Inc. | Microbial compositions and methods of use for canine enteropathy and dysbiosis |
| US20240263251A1 (en) * | 2021-02-19 | 2024-08-08 | Finch Therapeutics Holdings Llc | Compositions and methods for providing secondary bile acids to a subject |
| WO2023114180A1 (en) * | 2021-12-13 | 2023-06-22 | The Regents Of The University Of California | Compositions and methods for modifying bile acids to regulate lipid and steroid metabolism |
| CN114480562B (zh) * | 2022-01-27 | 2023-09-19 | 西南医科大学附属医院 | 一种基于pfor酶活性导向的fmt供体筛选方法及其应用 |
| US20230381248A1 (en) * | 2022-05-26 | 2023-11-30 | National Taiwan University Hospital | Method for treating and/or preventing atopy and allergic diseases by using bacteria or compositions having 7 alpha-dehydroxylase activity, and/or bile acid receptors fxr and/or tgr5 agonists |
| KR20240114298A (ko) | 2023-01-12 | 2024-07-23 | 에스엔제이 파마 인크 | 감염 저항성 장내 균주 및 그 용도 |
| WO2024218184A1 (en) | 2023-04-20 | 2024-10-24 | Ecole Polytechnique Federale De Lausanne (Epfl) | AN ANTIBIOTIC AND A MICROORGANISM HAVING BILE ACID 7α-DEHYDROXYLATION ACTIVITY FOR TREATING NON-INFECTIOUS DISEASES |
| WO2025093777A1 (en) * | 2023-11-05 | 2025-05-08 | Human Biome Institute S.A. | Functional compositions and methods of use thereof in the treatment and recurrence prophylaxis of clostridioides difficile infection and restoration of healthy microbiota |
| CN121260493A (zh) * | 2025-12-08 | 2026-01-02 | 上海交通大学医学院附属仁济医院 | 用于炎症性肠病的艰难梭菌感染发生与复发风险的预测模型构建系统及存储介质 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR950703640A (ko) | 1992-10-09 | 1995-09-20 | 가일 케이,나우톤. | 간 보존 세포(liver reserve cells) |
| JP4429422B2 (ja) * | 1999-09-06 | 2010-03-10 | 雪印乳業株式会社 | 抱合胆汁酸脱抱合酵素タンパク質 |
| AUPQ899700A0 (en) * | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| MXPA03009877A (es) * | 2001-05-04 | 2005-07-15 | Univ Florida | Clonacion y secuenciamiento de genes de piruvato decarboxilasa (pdc) a partir de bacterias y usos de los mismos. |
| US7909815B2 (en) | 2003-05-23 | 2011-03-22 | Civco Medical Instruments Co., Inc. | Instrument guide for use with needles and catheters |
| JP5620392B2 (ja) | 2008-11-03 | 2014-11-05 | タフツ ユニヴァーシティーTufts University | クロストリジウム・ディフィシレ胞子の発芽および伸長を阻害するための方法および組成物 |
| WO2012142605A1 (en) * | 2011-04-15 | 2012-10-18 | Samaritan Health Services | Rapid recolonization deployment agent |
| PT2750682T (pt) * | 2011-10-11 | 2016-07-26 | Achim Biotherapeutics Ab | Composição compreendendo a flora intestinal cultivada anaerobiamente |
| CN116942833A (zh) * | 2011-12-01 | 2023-10-27 | 国立大学法人 东京大学 | 诱导调节性t细胞的增殖或积累的人源细菌 |
| EP3686284A1 (en) * | 2012-05-18 | 2020-07-29 | Genome Research Limited | Methods and groups |
| US8906668B2 (en) * | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| EP3074027B1 (en) * | 2013-11-25 | 2024-12-18 | Seres Therapeutics, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
-
2015
- 2015-05-19 PT PT157960006T patent/PT3146065T/pt unknown
- 2015-05-19 US US15/312,610 patent/US20170087196A1/en not_active Abandoned
- 2015-05-19 EP EP24212532.6A patent/EP4527400A3/en active Pending
- 2015-05-19 EP EP25222653.5A patent/EP4684833A3/en active Pending
- 2015-05-19 WO PCT/US2015/031627 patent/WO2015179437A1/en not_active Ceased
- 2015-05-19 DK DK15796000.6T patent/DK3146065T3/da active
- 2015-05-19 FI FIEP15796000.6T patent/FI3146065T3/fi active
- 2015-05-19 CA CA2949232A patent/CA2949232A1/en active Pending
- 2015-05-19 ES ES15796000T patent/ES3000403T3/es active Active
- 2015-05-19 EP EP15796000.6A patent/EP3146065B1/en active Active
- 2015-05-19 AU AU2015264266A patent/AU2015264266A1/en not_active Abandoned
-
2019
- 2019-07-26 US US16/523,414 patent/US11471495B2/en active Active
-
2021
- 2021-06-30 AU AU2021204506A patent/AU2021204506A1/en not_active Abandoned
-
2022
- 2022-10-17 US US18/047,167 patent/US12414969B2/en active Active
-
2024
- 2024-01-12 AU AU2024200228A patent/AU2024200228A1/en active Pending
-
2025
- 2025-08-19 US US19/303,846 patent/US20260108564A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015264266A1 (en) | 2016-12-01 |
| EP4684833A3 (en) | 2026-03-25 |
| US20260108564A1 (en) | 2026-04-23 |
| US20230190825A1 (en) | 2023-06-22 |
| AU2021204506A1 (en) | 2021-07-29 |
| EP3146065A4 (en) | 2018-05-16 |
| EP3146065B1 (en) | 2024-11-13 |
| US20170087196A1 (en) | 2017-03-30 |
| CA2949232A1 (en) | 2015-11-26 |
| ES3000403T3 (en) | 2025-02-28 |
| EP4684833A2 (en) | 2026-01-28 |
| US11471495B2 (en) | 2022-10-18 |
| WO2015179437A1 (en) | 2015-11-26 |
| US12414969B2 (en) | 2025-09-16 |
| FI3146065T3 (fi) | 2025-02-12 |
| US20190381113A1 (en) | 2019-12-19 |
| EP4527400A2 (en) | 2025-03-26 |
| EP4527400A3 (en) | 2025-06-11 |
| DK3146065T3 (da) | 2025-01-06 |
| EP3146065A1 (en) | 2017-03-29 |
| AU2024200228A1 (en) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285565B (en) | Methods and preparations for immune modulation | |
| PT3146065T (pt) | Métodos e composições para reduzir a infecção por clostridium difficile | |
| GB2535253B (en) | Compositions and methods | |
| SG10202109655VA (en) | Compositions and methods for immunooncology | |
| SG10201609929QA (en) | Etching compositions and methods for using same | |
| EP3152319A4 (en) | Methods and compositions for nuclease design | |
| SG11201606702SA (en) | Methods and compositions for isolating exosomes | |
| IL249446A0 (en) | Preparations and methods for production packaging | |
| IL246879B (en) | Preparations of Epilimod and methods of using them | |
| IL250902A0 (en) | Anti-met antibodies and preparations | |
| GB201417828D0 (en) | New methods and compositions | |
| IL249226A0 (en) | Methods and preparations for immune modulation | |
| GB201421071D0 (en) | Compound for treating clostridium difficile | |
| ZA201607571B (en) | Compositions and methods for detecting huanglongbing | |
| SG11201510166YA (en) | Compositions and methods of immunizing against c. difficile | |
| SG11201610970UA (en) | Compositions and methods for enhancing immunity | |
| EP3097420A4 (en) | Methods and compositions for immune dis-inhibition | |
| PT3113774T (pt) | Composições de grapiprant e métodos de utilização das mesmas | |
| IL252190A0 (en) | Preparations against human cytomegalovirus and methods of treating it | |
| EP3227249A4 (en) | Compositions and methods for micronutrient introduction | |
| IL248513B (en) | Preparations and methods for immunomodulation against lyst | |
| PT3160500T (pt) | Composição imunogénica de clostridium difficile | |
| PT3160263T (pt) | Composições para prevenção de infeções | |
| EP3221366A4 (en) | Polyaminomethylbenzyloxalamides and compositions and methods related thereto | |
| GB201402915D0 (en) | Compositions and methods |